- Open Access
Correction to: Crystal structure of PKG Iβ holoenzyme reveals a trans‑inhibiting dimer assembly
Journal of Translational Medicine volume 18, Article number: 27 (2020)
- The original article was published in Journal of Translational Medicine 2019 17:254
Correction to: J Transl Med (2019) 17(Suppl 2):254 https://doi.org/10.1186/s12967-019-1994-0
After publication of abstract S 2‑06 in supplement , it was brought to our attention that the second author’s name is spelled incorrectly. Originally the author name has been published as Rajesh Sarma. The correct author name is Rajesh Sharma. The full text of abstract S 2-06 with the corrected author list can be found below.
S 2‑06 Crystal structure of PKG Iβ holoenzyme reveals a trans‑inhibiting dimer assembly
Choel Kim1,2, Rajesh Sharma1, Darren E. Casteel3
1Baylor College of Medicine, Pharmacology and Chemical Biology, Houston, TX, USA; 2Baylor College of Medicine, Biochemistry and Molecular Biology, Houston, TX, USA; 3University of California, San Diego, Medicine, La Jolla, CA, USA
Correspondence: Choel Kim - firstname.lastname@example.org
Journal of Translational Medicine 2019, 17(2): S2-06
Introduction: As the major molecular switch for regulation of smooth muscle/vascular tone and nociception, mammalian cGMP dependent protein kinase I is a promising therapeutic target for hypertensive diseases and chronic pain. The lack of structural information on the PKG holoenzyme has hindered a detailed understanding of its regulation, though the holoenzyme structure for cAMP dependent protein kinase (PKA) suggests plausible models for PKG regulatory (R) and catalytic (C) domain interactions in the inhibited state.
Methods: We determined a crystal structure of PKG Iβ holoenzyme complex at 2.3 Å that enables us to visualize the R–C interface of PKG Iβ of the inhibited state for the first time. Results: We crystallized a monomeric PKG Iβ that lacks the dimerization domain, but the asymmetric unit of the crystal contains a twofold symmetric dimer. The interfaces formed between PKG R and C domains are similar to those seen in the PKA Iα holoenzyme with the inhibitor sequence docked to the active site cleft. However, the overall topology unexpectedly reveals that the R domain of each PKG monomer binds the C domain of the other monomer, giving rise to inhibition in trans (Fig. 1).
Conclusions: In the light of previous PKG structural biology, this structure suggests that the PKG inhibited and activated states are stabilized by mutually exclusive domain–domain contacts that either occlude or expose the active site. Our previous structure of the activated state of the isolated PKG Iβ regulatory domain  identified a dimer formed by R–R domain interactions (mediated in part by interfacial cGMP). Results from other studies [3,4,5] suggest how these domain–domain contacts might be differentially stabilized by cyclic nucleotide binding, and how conformational changes associated with nucleotide binding might bias the topology of each fulllength monomer towards or away from the trans-inhibited dimer state. Because of sequence differences, PKG lacks some key local contacts that stabilize the PKA holoenzyme R–C interface, perhaps because PKA must overcome mass action to inactivate its catalytic domain, whereas native PKG is already pre-assembled as a dimer. These differences provide starting points for rationally modulating the PKG activation constant by mutagenesis to dissect the details of the mechanism of activation. The quaternary assembly seen in the trans-inhibiting dimer of PKG Iβ differs significantly from other kinases, suggesting a unique regulation mechanism for PKG I with implications for the kinetics, cooperativity, CNB domain nucleotide selectivity, and isotype-specificity of activation.
Meeting abstracts from the 9th International Conference on cGMP: Generators, Effectors and Therapeutic Implications. J Transl Med. 2019;17(Suppl 2):254. https://doi.org/10.1186/s12967-019-1994-0.
Kim JJ, Lorenz R, Arold ST, Reger AS, Sankaran B, Casteel DE, Herberg FW, Kim C. Crystal structure of PKG I:cGMP complex reveals a cGMPmediated dimeric interface that facilitates cGMP-induced activation. Structure. 2016;24:710–20.
Huang GY, Kim JJ, Reger AS, Lorenz R, Moon EW, Zhao C, Casteel DE, Bertinetti D, Vanschouwen B, Selvaratnam R, Pfugrath JW, Sankaran B, Melacini G, Herberg FW, Kim C. Structural basis for cyclic-nucleotide selectivity and cGMP-selective activation of PKG I. Structure. 2014;22:116–24.
Kim JJ, Casteel DE, Huang G, Kwon TH, Ren RK, Zwart P, Headd JJ, Brown NG, Chow DC, Palzkill T, Kim C. Co-crystal structures of PKG Ibeta (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding. PLoS ONE. 2011;6:e18413.
Qin L, Sankaran B, Aminzai S, Casteel DE, Kim C. Structural basis for selective inhibition of human PKG Ialpha by the balanol-like compound N46. J Biol Chem. 2018;293:10985–92.
This project was supported by National Institutes of Health Grant R01 GM090161 (CK) and by National Institutes of Health Grant RO1 HL132141 (DEC). The expression of PKG Iβ was supported in part by the Protein and Monoclonal Antibody Production Shared Resource at Baylor College of Medicine with funding from National Institutes of Health Cancer Center Support Grant P30 CA125123.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kim, C., Sharma, R. & Casteel, D.E. Correction to: Crystal structure of PKG Iβ holoenzyme reveals a trans‑inhibiting dimer assembly. J Transl Med 18, 27 (2020). https://doi.org/10.1186/s12967-019-02198-7